>>Signaling Pathways>> Tyrosine Kinase>> Src>>Src I1

Src I1

Catalog No.GC16957

Src I1은 IC50 값이 Src에 대해 44nM이고 Lck에 대해 88nM인 강력한 ATP-경쟁적 및 선택적 이중 사이트 Src 티로신 키나제 억제제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Src I1 Chemical Structure

Cas No.: 179248-59-0

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$40.00
재고 있음
2mg
US$35.00
재고 있음
5mg
US$49.00
재고 있음
10mg
US$67.00
재고 있음
25mg
US$154.00
재고 있음
50mg
US$277.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor with IC50 values of 44 nM for Src and 88nM for Lck.

Src-I1 is competitive with both ATP and peptide binding sites of the kinase. The IC50 values are 44 and 88 nM for Src and Lck, respectively[1]. Src-I1, is found to be a potent inhibitor of Src (IC50=0.18 μM), but also inhibited other Src family members, such as Lck, Csk and Yes with similar potency to Src, and RIP2 (IC50=0.026 μM) with even greater potency. In addition, it inhibited CHK2 with similar potency to Src, and Aurora B with slightly lower potency[2].

References:
[1]. Tian G, et al. Structural determinants for potent, selective dual site inhibition of human pp60c-src by 4-anilinoquinazolines. Biochemistry. 2001 Jun 19;40(24):7084-91.
[2]. Bain J, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.

리뷰

Review for Src I1

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Src I1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.